Neurocrine Biosciences reported $100K in Ordinary Share Capital for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
Agios Pharmaceuticals AGIO:US USD 71K 0
ALKERMES ALKS:US USD 1.69M 1000
Alnylam Pharmaceuticals ALNY:US USD 1.23M 20K
Amgen AMGN:US USD 32.37B 1.03B
Aptinyx Inc APTX:US USD 677K 0
Biogen BIIB:US USD 100K 0
Biomarin Pharmaceutical BMRN:US USD 186K 0
Cytokinetics CYTK:US USD 93K 8K
Exelixis EXEL:US USD 323K 1000
Halozyme Therapeutics HALO:US USD 135K 3K
Intercept Pharmaceuticals ICPT:US USD 41K 11K
Intra Cellular Therapies ITCI:US USD 9K 0
IONIS PHARMACEUT IONS:US USD 142K 0
Nektar Therapeutics NKTR:US USD 19K 0
Neurocrine Biosciences NBIX:US USD 100K 0
Regeneron Pharmaceuticals REGN:US USD 100K 0
Repligen RGEN:US USD 555K 0
Rigel Pharmaceuticals RIGL:US USD 173K 0
Sarepta Therapeutics SRPT:US USD 9K 0
Teva Pharmaceutical TEVA:IT USD 20.31B 387.03M
Ultragenyx Pharmaceutical RARE:US USD 70K 0
Vertex Pharmaceuticals VRTX:US USD 2.6M 0
Xoma XOMA:US USD 86K 0
YTE INCY:US USD 222K 0